Autres domaines


National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1 - 09/11/20

Doi : 10.1016/j.jaad.2020.09.001 
Joel M. Gelfand, MD, MSCE a, b, , April W. Armstrong, MD, MPH c, Stacie Bell, PhD d, George L. Anesi, MD, MSCE, MBE b, e, Andrew Blauvelt, MD, MBA f, Cassandra Calabrese, DO g, Erica D. Dommasch, MD, MPH h, Steve R. Feldman, MD, PhD i, Dafna Gladman, MD, FRCPC j, k, Leon Kircik, MD l, m, Mark Lebwohl, MD l, Vincent Lo Re, MD, MSCE b, n, George Martin, MD o, Joseph F. Merola, MD, MMSc p, Jose U. Scher, MD q, Sergio Schwartzman, MD r, James R. Treat, MD s, Abby S. Van Voorhees, MD t, Christoph T. Ellebrecht, MD a, Justine Fenner, MD l, Anthony Ocon, MD, PhD u, Maha N. Syed, MBBS a, Erica J. Weinstein, MD n, Jessica Smith, BS d, George Gondo, MA d, Sue Heydon, MA d, Samantha Koons, BS d, Christopher T. Ritchlin, MD MPH u
a Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania 
b Department of Biostatistics, Epidemiology and Informatics and the Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 
c Department of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles, California 
d National Psoriasis Foundation, Portland, Oregon 
e Division of Pulmonary, Allergy, and Critical Care, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania 
f Oregon Medical Research Center, Portland, Oregon 
g Department of Rheumatology and Immunology, Cleveland Clinic, Cleveland, Ohio 
h Department of Dermatology, Harvard Medical School, Boston, Massachusetts 
i Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, North Carolina 
j Krembil Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada 
k Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada 
l Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York 
m Department of Dermatology, Indiana University Medical Center, Indianapolis, Indiana 
n Division of Infectious Diseases, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 
o Dermatology Associates, Maui, Hawaii 
p Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 
q Division of Rheumatology, Department of Medicine, New York University Grossman School of Medicine and New York University Langone Orthopedic Hospital, New York, New York 
r Department of Rheumatology, Hospital for Special Surgery, New York, New York 
s Department of Pediatric Dermatology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania 
t Department of Dermatology, Eastern Virginia Medical School, Norfolk, Virginia 
u Division of Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, New York 

Correspondence to: Joel M. Gelfand, MD, MSCE, Department of Dermatology, Perelman Center for Advanced Medicine, 3400 Civic Center Blvd, Philadelphia, PA, 19104.Department of DermatologyPerelman Center for Advanced Medicine3400 Civic Center BlvdPhiladelphiaPA19104

Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.

Connectez-vous pour en bénéficier!



To provide guidance about management of psoriatic disease during the coronavirus disease 2019 (COVID-19) pandemic.

Study design

A task force (TF) of 18 physician voting members with expertise in dermatology, rheumatology, epidemiology, infectious diseases, and critical care was convened. The TF was supplemented by nonvoting members, which included fellows and National Psoriasis Foundation (NPF) staff. Clinical questions relevant to the psoriatic disease community were informed by questions received by the NPF. A Delphi process was conducted.


The TF approved 22 guidance statements. The average of the votes was within the category of agreement for all statements. All guidance statements proposed were recommended, 9 with high consensus and 13 with moderate consensus.


The evidence behind many guidance statements is limited in quality.


These statements provide guidance for the management of patients with psoriatic disease on topics ranging from how the disease and its treatments impact COVID-19 risk and outcome, how medical care can be optimized during the pandemic, what patients should do to lower their risk of getting infected with severe acute respiratory syndrome coronavirus 2 and what they should do if they develop COVID-19. The guidance is intended to be a living document that will be updated by the TF as data emerge.

Le texte complet de cet article est disponible en PDF.

Key words : biologics, COVID-19, psoriasis, psoriatic arthritis, SARS-CoV-2

Abbreviations used : CDC, COVID-19, NPF, SARS COV-2, TF, TNF


 Funding sources: None.
 Conflicts of interest: Dr Anesi has pending fees from UpToDate for authoring COVID-19 clinical reference material, and research time is supported by the Agency for Healthcare Research and Quality K12HS026372. Dr Armstrong has served as a research investigator and/or scientific advisor to LEO Pharma, AbbVie, UCB, Janssen, Eli Lilly and Company, Novartis, Ortho Dermatologics, Sun, Dermavant, BMS, Sanofi, Regeneron, Dermira, and Modmed. Dr Blauvelt has served as a scientific adviser and/or clinical study investigator for AbbVie, Almirall, Arena, Athenex, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, Eli Lilly and Company, Forte, Galderma, Incyte, Janssen, LEO Pharma, Novartis, Pfizer, Rapt, Regeneron, Sanofi Genzyme, Sun Pharma, and UCB Pharma, and as a paid speaker for AbbVie. Authors Bell, Gondo, Heydon, Koons, and Smith are employees of the National Psoriasis Foundation. Dr Calabrese is a speaker for Sanofi-Regeneron and a consultant for AbbVie. Dr Feldman received research, speaking, and/or consulting support from Galderma, GSK/Stiefel, Almirall, Alvotech, LEO Pharma, BMS, Boehringer Ingelheim, Mylan, Celgene, Pfizer, Ortho Dermatology, AbbVie, Samsung, Janssen, Lilly, Menlo, Merck, Novartis, Regeneron, Sanofi, Novan, Qurient, National Biological Corporation, Caremark, Advance Medical, Sun Pharma, Suncare Research, Informa, UpToDate, and the National Psoriasis Foundation. Dr Feldman also consults for others through Guidepoint Global, Gerson Lehrman, and other consulting organizations, is the founder and majority owner of www.DrScore.com, and is also a founder and part owner of Causa Research, a company dedicated to enhancing patients' adherence to treatment. Dr Gelfand served as a consultant for Bristol-Myers Squibb, Boehringer Ingelheim, GlaxoSmithKline, Janssen Biologics, Novartis Corp, Regeneron, UCB (Data Safety and Monitoring Board), Sanofi, and Pfizer, receiving honoraria; in addition, he receives research grants (to the Trustees of the University of Pennsylvania) from AbbVie, Janssen, Novartis, Sanofi, Celgene, Ortho Dermatologics, and Pfizer, has received payment for CME work related to psoriasis that was supported indirectly by Eli Lilly and Company and Ortho Dermatologics, is a co-patent holder of resiquimod for treatment of cutaneous T-cell lymphoma, and is a deputy editor for the Journal of Investigative Dermatology, receiving honoraria from the Society for Investigative Dermatology. Dr Gladman is a consultant for AbbVie, Amgen, BMS, Galapagos, Gilead, Eli Lilly and Company, Janssen, Novartis, Pfizer, and UCB, and receives grants from AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. Dr Kircik has served as an investigator, consultant, or speaker for AbbVie, Almirall, Amgen, Arcutis, Bausch Health Canada, Bristol-Myers Squibb, Boehringer Ingelheim, Cellceutix, Celgene, Coherus, Dermavant, Dermira, Eli Lilly and Company, LEO Pharma, MC2, Maruho, Novartis, Ortho Dermatologics, Pfizer, Dr. Reddy's Laboratories, Sun Pharma, UCB, Taro, and Xenoport. Dr Lebwohl is an employee of Mount Sinai and receives research funds from AbbVie, Amgen, Arcutis, Boehringer Ingelheim, Dermavant, Eli Lilly and Company, Incyte, Janssen Research & Development, LLC, LEO Pharma, Ortho Dermatologics, Pfizer, and UCB, and is a consultant for Aditum Bio, Allergan, Almirall, Arcutis Inc, Avotres Therapeutics, BirchBioMed Inc, BMD Skincare, Boehringer-Ingelheim, Bristol-Myers Squibb, Cara Therapeutics, Castle Biosciences, Corrona, Dermavant Sciences, Evelo, Facilitate International Dermatologic Education, Foundation for Research and Education in Dermatology, Inozyme Pharma, Kyowa Kirin, LEO Pharma, Meiji Seika Pharma, Menlo, Mitsubishi, Neuroderm, Pfizer, Promius/Dr. Reddy's Laboratories, Serono, Theravance, and Verrica. Dr Martin is a consultant for Almirall, Athenex, Bristol-Meyers Squibb, Celgene, Eli Lilly and Company, LEO Pharma, Ortho Dermatologic, Pfizer, and UCB, and is a scientific advisor for Almirall, Athenex, Bristol-Meyers Squibb, Celgene, Eli Lilly and Company, Janssen, LEO Pharma, Ortho Dermatologic, Pfizer, and UCB. Dr Merola is a consultant and/or investigator for Bristol-Myers Squibb, AbbVie, Dermavant, Eli Lilly and Company, Novartis, Janssen, UCB, Sun Pharma, Pfizer, and EMD Sorono. Dr Ritchlin reports personal fees from AbbVie, Amgen, Janssen, Novartis, UCB, and Boerhinger Ingelheim, and grants from Amgen, UCB, and AbbVie outside the submitted work. Dr Schwartzman is a speaker for AbbVie, Genentech, Janssen, Eli Lilly and Company, Novartis, Pfizer, and UCB, owns stock in Amgen, Boston Scientific, Gilead, Medtronic, and Pfizer, is a consultant for AbbVie, Myriad, Janssen, Gilead, Eli Lilly and Company, Novartis, and UCB, is a scientific advisory board member for Myriad, and is a board member of the National Psoriasis Foundation. Dr Scher is a consultant for UCB, Janssen, AbbVie, Pfizer, Novastis, and Sanofi. Dr Syed is supported by a grant from Pfizer. Dr Van Voorhees has been an investigator for Celgene, Eli Lilly and Company, and AbbVie, and has been an advisor/consultant for AbbVie, Allergan, AstraZeneca, Celgene, Dermira, Merck, Novartis, Pfizer, UCB, and Valeant. Drs Weinstein, Ellebrecht, Ocon, Fenner, Treat, Dommasch, and Lo Re have no conflicts of interest to disclose.
 IRB approval status: Not applicable.
 Reprints not available from the authors.

© 2020  American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer

    Export citations

  • Fichier

  • Contenu

Vol 83 - N° 6

P. 1704-1716 - décembre 2020 Retour au numéro
Article précédent Article précédent
  • Antecedent immunosuppressive therapy for immune-mediated inflammatory diseases in the setting of a COVID-19 outbreak
  • Jesse Veenstra, Connor R. Buechler, Gabrielle Robinson, Stephanie Chapman, Madeline Adelman, Aaron Tisack, Peter Dimitrion, Erika Todter, Laurie Kohen, Henry W. Lim
| Article suivant Article suivant
  • Isolated nail lichen planus: An expert consensus on treatment of the classical form
  • Matilde Iorizzo, Antonella Tosti, Michela Starace, Robert Baran, C. Ralph Daniel, Nilton Di Chiacchio, Sophie Goettmann, Chander Grover, Eckart Haneke, Shari R. Lipner, Phoebe Rich, Bertrand Richert, Dimitris Rigopoulos, Adam I. Rubin, Martin Zaiac, Bianca Maria Piraccini

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Mon compte

Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.